Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc.
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of ...
Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...
Denmark is updating the wage levels used to assess work permit applications from October 1st, meaning most applicants will ...
Marcus Remmers, a partner of the Planetary Health Investments team of Novo Holdings, the controlling shareholder of Novo ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
COPENHAGEN: Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss ...
Investor's Business Daily on MSN1d
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss DrugNovo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback